Abstract
Rituximab is a mouse/human chimeric IgG1κ monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B-lymphocytes. The mechanisms of action of rituximab involve complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), antibody dependent cellular cytotoxicity (ADCC) and induction of apoptosis. Pharmacokinetic issues, tumor and molecular related factors mediate resistance to rituximab. Optimizing rituximab treatment requires a therapeutic project that might ideally be individualized and that includes enhancing of ADCC and CDC mechanisms, acting over apoptosis-regulating proteins and using synergistic conventional chemotherapeutic agents. Pharmacokinetic favourable schedules in specific diseases alone or associated to chemotherapeutic agents are not well known, therefore studies focusing on these issues are warranted. New information regarding targeting the lymphoma microenvironment and rituximab effects is the focus of current research.
Keywords: Rituximab, lymphoma, treatment, pharmacokinetic
Reviews on Recent Clinical Trials
Title: Pharmacokinetic Properties of Rituximab
Volume: 3 Issue: 1
Author(s): Jose Rodriguez and Antonio Gutierrez
Affiliation:
Keywords: Rituximab, lymphoma, treatment, pharmacokinetic
Abstract: Rituximab is a mouse/human chimeric IgG1κ monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B-lymphocytes. The mechanisms of action of rituximab involve complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), antibody dependent cellular cytotoxicity (ADCC) and induction of apoptosis. Pharmacokinetic issues, tumor and molecular related factors mediate resistance to rituximab. Optimizing rituximab treatment requires a therapeutic project that might ideally be individualized and that includes enhancing of ADCC and CDC mechanisms, acting over apoptosis-regulating proteins and using synergistic conventional chemotherapeutic agents. Pharmacokinetic favourable schedules in specific diseases alone or associated to chemotherapeutic agents are not well known, therefore studies focusing on these issues are warranted. New information regarding targeting the lymphoma microenvironment and rituximab effects is the focus of current research.
Export Options
About this article
Cite this article as:
Rodriguez Jose and Gutierrez Antonio, Pharmacokinetic Properties of Rituximab, Reviews on Recent Clinical Trials 2008; 3 (1) . https://dx.doi.org/10.2174/157488708783330495
DOI https://dx.doi.org/10.2174/157488708783330495 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Synthesis and Cytotoxic Evaluation for Some New Dihydropyrimidinone Derivatives for Anticancer Activity
Letters in Drug Design & Discovery Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction
Reviews on Recent Clinical Trials DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Marine Derived Bioactive Compounds for Breast and Prostate Cancer Treatment: A Review
Current Bioactive Compounds EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Epigenetics and Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Ring Opening of Tetrazole via Unusual Vilsmeir-Haack Reaction Forming Novel Triazenes
Letters in Organic Chemistry Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
CNS & Neurological Disorders - Drug Targets Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?
Current Gene Therapy Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism